04 October, 2022 in Allgemein Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming
05 September, 2022 in Allgemein Pantherna Therapeutics collaborates with Charité – Universitätsmedizin Berlin to investigate the potential of therapeutic mRNA in autoimmune disease
11 January, 2022 in Uncategorized Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs
15 November, 2021 in Allgemein Astellas and Pantherna Enter into Technology Evaluation Agreement for Research of mRNA-based Regenerative Medicine.
12 June, 2020 in Allgemein Pantherna Therapeutics GmbH signs an agreement for technology evaluation with Astellas Innovation Management LLC to evaluate Pantherna’s lipid nanoparticle transport system and mRNA molecules.
02 April, 2020 in Allgemein Successful follow-up financing for Pantherna Therapeutics’ development programs to fight Acute Respiratory Distress Syndrome
26 March, 2020 in Allgemein Pantherna Therapeutics GmbH and PROVIREX Genome Editing Therapies GmbH are developing lipid-based delivery systems for mRNA-directed genome editing of lymphocytes for the treatment of HIV and other life-threatening persistent viral diseases
